In silico prediction of brain and CSF permeation of small molecules using PLS regression models

被引:36
作者
Bendels, Stefanie [1 ]
Kansy, Manfred [1 ]
Wagner, Bjoern [1 ]
Huwyler, Joerg [2 ]
机构
[1] F Hoffmann La Roche Ltd, Pharmaceut Res, CH-4070 Basel, Switzerland
[2] Univ Appl Sci NW Switzerland, Inst Pharma Technol, CH-4132 Muttenz, Switzerland
关键词
blood-brain barrier; CSF-plasma and brain-plasma ratios; PLS model; CNS active; passive transcellular transport;
D O I
10.1016/j.ejmech.2007.11.011
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Computational partial least square (PLS) regression models were developed, which can be applied to predict central nervous system (CNS) penetration of drug-like organic molecules. For modeling, a dataset of 77 structurally diverse compounds was used with reported steady-state rat brain to plasma ratios (BPR). Information on steady-state cerebrospinal fluid distribution (CSF to plasma ratio or CSFPR) was available for 37 of these compounds. The molecules were from different chemical series and included bases, acids, zwitterions and neutral molecules. They were CNS active and were therefore assumed to penetrate the blood-brain barrier and/or the blood-liquor barrier. Using these PLS models, the dataset could be described accurately (r(2) = 0.78, StErrorEst = 0.30 and r(2) = 0.75, StErrorEst = 0.28 for BPR and CSFPR, respectively). Molecular descriptors used for the prediction of passive membrane transport were lipophilicity, polar and hydrophobic surface areas as well as structural parameters and net charge at physiological pH. There was no apparent correlation between experimental brain and CSF exposure. Consequently, different PLS models and guiding rules were developed and discussed for the prediction of BPR or CSFPR. The present models provide a cost-effective and efficient strategy to guide synthetic efforts in medicinal chemistry at an early stage of the drug discovery and development process. (c) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1581 / 1592
页数:12
相关论文
共 47 条
[1]  
ADAM G, 2001, Patent No. 2001029012
[2]  
Adam G., 2001, [No title captured], Patent No. [EP 10,74,549, 1074549, 01074549]
[3]  
ALANINE A, 2001, Patent No. 1088818
[4]   PARTITIONING OF IONIZING MOLECULES BETWEEN AQUEOUS BUFFERS AND PHOSPHOLIPID-VESICLES [J].
AUSTIN, RP ;
DAVIS, AM ;
MANNERS, CN .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (10) :1180-1183
[5]  
Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100
[6]   The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison [J].
Ballard, TM ;
Woolley, ML ;
Prinssen, E ;
Huwyler, J ;
Porter, R ;
Spooren, W .
PSYCHOPHARMACOLOGY, 2005, 179 (01) :218-229
[7]  
BINGGELI A, 2002, Patent No. 2002098864
[8]  
BOES M, 2000, Patent No. 2000053572
[9]  
BORRONI EM, 2001, Patent No. 2001062233
[10]  
CAI HY, 2002, Patent No. 2002092604